News
-
-
PRESS RELEASE
Formycon and Zydus: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by FDA
Formycon and Zydus announce FDA review of FYB206, first publicly announced Keytruda biosimilar filing, marking regulatory milestone under licensing agreement with Zydus. Could accelerate access to cancer therapy for patients -
-
PRESS RELEASE
Formycon Optimizes Biosimilar Development with AI-Powered Technologies: Digital Solutions Enhance Development Efficiency as Part of the FYB4GROWTH Strategy
Formycon optimizes biosimilar development with AI-powered technologies to enhance efficiency and competitiveness as part of the FYB4GROWTH strategy -
-
PRESS RELEASE
Formycon sets Benchmark in Biosimilar Development: Scientific Foundation of the innovative Development Program for FYB206 published in the Journal BioDrugs
Formycon sets a benchmark in biosimilar development with the publication of the scientific foundation of the innovative development program for FYB206 in the Journal BioDrugs -
-
PRESS RELEASE
Formycon reports key operational achievements in the first half of 2026 and significantly improves financial results year-on-year
Formycon reports key operational achievements in the first half of 2026 and significantly improves financial results year-on-year. Successful clinical development enhances Formycon's position in biosimilars -
-
